-
Laboratory Studies of Peripheral Blood and Bone Marrow Cells Isolated From Patients with Clonal Myeloid or Lymphoproliferative Disorders
The major purpose of this research project is to provide laboratory scientists with human tissue for laboratory experiments which may ...
Exact
Phase N/A
-
IUCRO-0216; Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
The purpose of this study is to provide a central collection bank to store blood, urine, bone marrow, leukapheresis and ...
Exact
Phase N/A
-
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease An Exploratory Model
The purpose of this research is to learn if substances that cause bone destruction are increased in multiple myeloma patient ...
Exact
Phase N/A
-
A Path Analysis Modeling of the Interaction of AXII and/or AXIIR with the Changes in Cytokines and Myeloma Bone ...
The purpose of this research study is to learn if substances that cause bone destruction are increased in the blood ...
Exact
Phase N/A
-
E4412; A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with ...
This phase I trial studies the side effects and best dose of ipilimumab when given together with brentuximab vedotin in ...
Exact
Phase N/A
-
E1A11; Randomized Phase III Trial of Bortezomib Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib Lenalidomide Dexamethasone (CRd) Followed by Limited or ...
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide ...
Exact
Phase N/A
-
IUCRO-0498; Role of Osteocytes in Myeloma Bone Disease
The purpose of this study is to learn if substances that may cause bone destruction are increased in blood or ...
Exact
Phase N/A
-
A Randomized Phase II Trial of Brentuximab Vedotin (SGN35 NSC# 749710) or Crizotinib (NSC#749005 Commercially Labeled) in Combination With ...
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients ...
Exact
Phase N/A
-
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- ...
This randomized phase III clinical trial compares how well combination chemotherapy works when given with or without bortezomib in treating ...
Exact
Phase N/A
-
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
This randomized phase III trial compares how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell ...
Exact
Phase N/A
Showing - of studies